The Brain’s Breakdown: Biomarkers and ECM in Neuroinflammation and Neurodegeneration
The brain is more than just neurons; it is a complex, finely tuned environment shaped by the extracellular matrix (ECM) and molecular signaling.
This webinar examines the structure and function of the brain ECM, emphasizing its influence on neural plasticity, signaling, and repair. After establishing a foundation in ECM biology, we will explore how this network interacts with disease mechanisms and why it has become a central focus in neuroscience.
A major topic will be the growing importance of biomarkers in neurodegenerative and neuroinflammatory disease research. Notably, phosphorylated tau at threonine 217 (pTau217) has emerged as a promising diagnostic marker for Alzheimer’s disease, representing a significant advance in early detection.
However, identifying equally robust and specific biomarkers for conditions such as Parkinson’s disease and multiple sclerosis remains challenging, with unresolved issues in diagnosis, prognosis, subtyping, and assessment of drug efficacy.
The webinar will conclude by examining how insights into brain ECM dynamics and disease-specific molecular profiles can drive drug discovery and therapeutic innovation, offering new opportunities to develop targeted treatments and improve clinical outcomes.
Read more
This webinar examines the structure and function of the brain ECM, emphasizing its influence on neural plasticity, signaling, and repair. After establishing a foundation in ECM biology, we will explore how this network interacts with disease mechanisms and why it has become a central focus in neuroscience.
A major topic will be the growing importance of biomarkers in neurodegenerative and neuroinflammatory disease research. Notably, phosphorylated tau at threonine 217 (pTau217) has emerged as a promising diagnostic marker for Alzheimer’s disease, representing a significant advance in early detection.
However, identifying equally robust and specific biomarkers for conditions such as Parkinson’s disease and multiple sclerosis remains challenging, with unresolved issues in diagnosis, prognosis, subtyping, and assessment of drug efficacy.
The webinar will conclude by examining how insights into brain ECM dynamics and disease-specific molecular profiles can drive drug discovery and therapeutic innovation, offering new opportunities to develop targeted treatments and improve clinical outcomes.
Read more